Ultragenyx to Host Conference Call for Third Quarter 2020 Financial Results and Corporate Update

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced a conference call scheduled for October 27, 2020, at 5 PM ET to discuss its third quarter 2020 financial results and provide a corporate update. The call will be accessible via the company's website, and participants can join by phone. Ultragenyx focuses on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases, aiming for efficient drug development to address high unmet medical needs.

Positive

• Focused on developing novel therapies for rare and ultra-rare genetic diseases.
• Management team experienced in rare disease therapeutics.
• Plans to deliver safe and effective therapies efficiently.

Negative

• None.

NOVATO, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, October 27, 2020 at 5pm ET to discuss third quarter 2020 financial results and provide a corporate update.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial (855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 4067577. The replay of the call will be available for one year.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370

 

FAQ

What is the date and time of Ultragenyx's Q3 2020 earnings call?

The earnings call is scheduled for October 27, 2020, at 5 PM ET.

How can I access the Q3 2020 earnings call for Ultragenyx?

You can access the call via the company's website or by dialing (855) 797-6910 (USA) or (262) 912-6260 (International).

What does Ultragenyx Pharmaceutical focus on?

Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases.

Who can I contact for investor relations at Ultragenyx?

For investor relations, you can contact Joshua Higa at 415-475-6370.